Project description:Severe acute respiratory virus-2 (SARS-CoV2) has spread globally leading to a devastating loss of life. Large registry studies have begun to shed light on the epidemiological and clinical vulnerabilities of cancer patients who succumb to or endure poor outcomes of SARS-CoV-2. Specific treatment for COVID-19 infections in cancer patients is lacking while the demand for treatment is increasing. Therefore, we explored the effect of Rintatolimod (Ampligen), a Toll-like receptor 3 (TLR3) agonist, to treat uninfected human pancreatic cancer cells (HPACs). The direct effect of Rintatolimod was measured by targeted gene expression profiling and by proteomics measurements. Our results showed that Rintatolimod induces an antiviral effect in HPACs by inducing RNase L- dependent and independent pathways of the innate immune system. Treatment with Rintatolimod activated the interferon signaling pathway, leading to the overexpression of several cytokines and chemokines in epithelial cells. Furthermore, Rintatolimod treatment increased the expression of angiogenesis-related genes without promoting fibrosis, which is the main cause of death in COVID-19 infected patients. We conclude that Rintatolimod could be considered an early additional treatment option for cancer patients who are infected with SARS-CoV-2 to prevent the complicated severity of the disease.

2022-02-17 | PXD026116 | Pride

COVID-19 provides an opportunity to advance a sustainable UK fisheries policy in a post-Brexit brave new world.

Project description: Not available

| S-EPMC7351025 | biostudies-literature

Cohort survey of healthcare workers with COVID-19 infection

Project description: Not available

| S-BSST563 | biostudies-other

Early Treatment of COVID-19 Disease: A Missed Opportunity.

Project description: Not available

| S-EPMC7553378 | biostudies-literature